Nomura analyst Christopher Marai raised the price target on Voyager Therapeutics (NASDAQ: VYGR) to $37.00 (from $26.00) while maintaining a Buy rating.
Analyst says: “VYGR announced a restructured deal with Sanofi: VYGR now has WW rights to VY-HTT01 for Huntington’s disease, and the ex-U.S. rights to VYFXN01 for Friedreich’s ataxia have now been transferred to NBIX. SNY has option rights to novel AAV capsids for up to two non-CNS indications. VYGR will pay SNY $10mn, but receive $5mn from NBIX. We increase our target price to $37 from $26, adjusting for the transaction, but note that VYGR is nearing a ″local maximum″ in terms of valuation, in our view; however, we see continued upside potential over the next 12 months.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.